<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01062737</url>
  </required_header>
  <id_info>
    <org_study_id>PR 2898</org_study_id>
    <nct_id>NCT01062737</nct_id>
  </id_info>
  <brief_title>Evaluation of the Structure Modifying Effect of Avocado-Soybean Unsaponifiables in Hip Osteoarthritis</brief_title>
  <acronym>ERADIAS</acronym>
  <official_title>Evaluation of the Structure-modifying Effect and Safety of Avocado-Soybean Unsaponifiable (Piascledine 300) in Hip Osteoarthritis (OA) a 3 Years Multicenter Randomized, Double Blind, Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Expanscience S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires Expanscience S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the long term (three years) ability of ASU (Avocado Soya
      unsaponifiable) to slow the decrease of radiographic JSW (Joint Space Width) in hip
      osteoarthritis (OA). This is a randomized, double blind, comparative, parallel group study
      versus placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria:

      Primary hip OA, fulfilling ACR criteria, patient over 45 y, painful &gt; 1 year, Lequesne's
      index &gt; or equal to 3, with minimum JSW at the target hip &gt; 1 mm and &lt; 4 mm on pelvic
      radiograph.

      Primary criterion of efficacy:

      The main criterion of efficacy is the change of JSW between baseline and end point. JSW is
      measured on the narrowest joint on pelvic or target hip X ray by blinded reader.

      Randomisation is stratified according JSW at baseline (&lt; 2,5 mm or &gt; or equal to 2,5 mm).

      Statistical analysis:

      The Full Analysis Set (FAS) is defined by patients with at least one baseline value and one
      post baseline value.

      The main analysis is scheduled on FAS using a Missing At Random (MAR)with a multiple model
      repeated measure (MMRM)to take in account missing value.

      SAP (Statistical Analysis Plan) schedule to analyse JSW change as quantitative variable using
      an ANCOVA and as qualitative variable (progressors defined as JSW loss upper than 0,5 mm)
      using Mantel Haentzel test.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>The main criterion of efficacy is the change of JSW between baseline and end point. JSW is measured on the narrowest joint on pelvic or target hip X ray by blinded reader.</measure>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <condition>Hip Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>ASU (Avocado Soybean Unsaponifiable)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASU</intervention_name>
    <arm_group_label>ASU (Avocado Soybean Unsaponifiable)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary OA of hip,

          -  ACR criteria,

          -  older than 45 years,

          -  symptomatic painful &gt; 1 an,

          -  Lequesne's index &gt; or equal to 3,

          -  JSW between 1 and 4 mm on pelvic radiograph.

        Exclusion Criteria:

          -  secondary OA.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Multiple locations</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2010</study_first_submitted>
  <study_first_submitted_qc>February 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2010</study_first_posted>
  <last_update_submitted>February 3, 2010</last_update_submitted>
  <last_update_submitted_qc>February 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Pr Michel Lequesne</name_title>
    <organization>Principal investigator</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

